Market Outlook and Forecast

Test Report second – 2026 To 2036

Updated Date: 11 Sep 2026 Delivery Time: 48 to 72 hours Markets: G8, G7, EU5 File format: Excel, PDF, PPT Request Free Sample

Gorlin Syndrome Market Outlook and Forecast

Thelansis’s “Gorlin Syndrome Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gorlin Syndrome treatment options for eight major markets (United States, Germany, France, Italy, Spain, UK, Japan, and China).

Market Size & Forecast

The Gorlin syndrome market is small but concentrated. Today, spend comes from off-label and repurposed options: surgical care, topicals and procedures, and the hedgehog inhibitors vismodegib and sonidegib, which are approved for advanced BCC rather than for Gorlin syndrome itself. The report sizes the 2026 market across the G8 (US, EU5, Japan, China) by country, drug class, and line of therapy. Our patient-based, bottom-up forecast runs from the diagnosed prevalent pool through the drug-treated population, line of therapy, uptake and net price, with a top-down cross-check validating each output. The forecast shows how a first Gorlin-specific preventive therapy could change market structure from 2026 to 2036.

Market Outlook Insights

Revenue is driven by the first approval of a Gorlin-specific therapy and by the shift from reactive tumor removal toward prevention. Slower or limited uptake would constrain it. The outlook covers launch timing and the impact of pivotal outcomes. It also covers pricing and reimbursement in a rare-disease population, and the range of scenarios built into the model.

Disease Burden, Epidemiology & Patient Pool

Disease Burden

Gorlin syndrome is an autosomal dominant condition, most often caused by PTCH1 variants. It predisposes patients to multiple basal cell carcinomas (BCCs), usually from adolescence or early adulthood. It also causes odontogenic keratocysts, palmar/plantar pits, skeletal and ocular abnormalities, and an increased risk of medulloblastoma, particularly with SUFU variants. Some patients develop only a few BCCs, while others develop hundreds or more over a lifetime. The result is repeated surgeries, cumulative scarring and a lifelong need for surveillance across dermatology, oncology, dental, genetics, and neurology.

Incidence & Prevalence, Diagnosed & Drug-Treated Population

Published prevalence estimates range from roughly 1 in 31,000 to 1 in 164,000, depending on geography and methodology. The report provides country-level incidence, prevalent, diagnosed, drug-treatable and drug-treated populations for 2026-2036 across the G8. Epidemiology for up to 31 countries is available in the Thelansis knowledge database. In the US 2026, Thelansis has projected ~17,790 prevalent cases, ~13,876 diagnosed & 162 incident diagnosed cases.

Patient Segmentation & Comorbidities

Patients are segmented by:

  1. Cumulative tumor burden (1–30, 31–100, >100 tumors)
  2. Genotype (PTCH1, SUFU, unknown)
  3. Age and Treatment cohort
  4. Clinical features, including keratocysts, BCC location, skeletal, ophthalmic and neurological involvement
  5. Treatment received
  6. Line of therapy

Treatment Landscape & Unmet Needs

Current Therapies

No drug is currently approved specifically for Gorlin syndrome. Management relies on surgery and procedural options, topicals (imiquimod, 5-FU), photodynamic therapy, retinoids, and the hedgehog inhibitors Erivedge (vismodegib) and Odomzo (sonidegib). PD-1 inhibitors are used in later lines for advanced disease.

Treatment Algorithm & Dx and Tx Journey

The report maps the patient journey from first presentation (often jaw cysts or early BCCs) through genetic confirmation, surveillance and first-line to fourth-line management. It includes region-specific differences across the G8.

Drug Classes & Mechanisms of Action

Covers hedgehog pathway (SMO) inhibitors, topical immunomodulators and cytotoxics, photodynamic therapy, retinoids, immune checkpoint inhibitors and emerging modalities.

Novel Treatment Modalities

Includes topical hedgehog inhibition (SGT-610/patidegib), other topical and repurposed agents in development, and early-stage approaches such as locally injectable options for odontogenic keratocysts.

Unmet Needs & Treatment Gaps

Key gaps are the lack of an approved preventive therapy, hedgehog inhibitor side effects that limit long-term use, no approved option addressing non-BCC manifestations, and the high cumulative surgical burden. Access to genetic testing and multidisciplinary care is also uneven across countries.

Key Market Trends and Growth Drivers

Market Trends & Treatment Evolution

The standard of care is moving from reactive management (excision, Mohs, cryotherapy, imiquimod, 5-FU, PDT, radiation avoided where possible) toward targeted and preventive approaches. Systemic hedgehog inhibitors reduce tumor burden but are limited by tolerability. This is pushing development toward topical and locally delivered options with better safety.

Market Growth Drivers & Barriers

  • Drivers: Orphan and breakthrough-designated late-stage assets; better genetic testing and earlier diagnosis; a growing diagnosed pool; recognition of the need to prevent BCCs rather than only treat them.
  • Barriers: A small patient pool; tolerability and persistence challenges with oral hedgehog inhibitors; clinical trial complexity; payer scrutiny of rare-disease pricing; heterogeneity across regions.

Future Opportunities

These include a first preventive therapy, new options for keratocysts and other manifestations, label expansion into high-frequency BCC, earlier pediatric and young-adult intervention, and genotype-guided care.

Trial Outcome Analysis

Clinical Trial Endpoints & Results

The report reviews pivotal and mid-stage programs, including endpoint design, comparators, and efficacy and safety outcomes. The most closely watched is Sol-Gel's global, randomized, double-blind, vehicle-controlled Phase 3 of SGT-610 (patidegib gel 2%). It enrolled 113 adults, of whom 102 completed 12 months of twice-daily facial application. Its endpoint is the number of new BCCs on the face. The last patient visit has been completed, and top-line results are expected in late November 2026. We will update the report content and forecast model with the readout.

KOL Insights

Interviews with dermatologists, medical oncologists, geneticists and Gorlin syndrome specialists cover the clinically meaningful efficacy threshold, the safety and tolerability needed for chronic use, expectations for target product profiles, and views on pricing and reimbursement across the United States, EU5, Japan, and China.

Treatment Adoption & Barriers

Covers the factors likely to shape uptake: strength of the efficacy signal, safety, convenience of use, payer acceptance, specialist awareness, and how much of the patient pool a therapy could realistically reach.

Market Segmentation & Geographic Opportunity

Market Segmentation by Drug Class

Hedgehog pathway inhibitors, topical therapies, surgical interventions, radiotherapy, immunotherapy and other emerging targeted therapies, with 2026 and 2036 share.

Market Segmentation by Patient Population

By genotype, tumor burden, age cohort and disease severity.

Market Segmentation by Line of Therapy

First- to fourth-line patient and revenue pools, including relapsed and refractory populations.

Market Opportunity Across G8 Markets or by Country & Region

Country-level views for the United States, Germany, France, Italy, Spain, the UK, Japan and China, plus regional views for Asia Pacific, Europe, North America, the Middle East, Africa and Latin America. Additional countries can be added to the dashboard on request.

Research Methodology

Patient-Based Forecasting Methodology

The forecast follows the Thelansis funnel: population → incidence → prevalence → diagnosed → drug-treatable → drug-treated → target patients → patients on product. Persistence, compliance and dosing then convert patients to volume, and pricing and reimbursement convert volume to sales.

Market Forecast Model & Assumptions

Uptake is modeled using analog, attribute and conjoint-based approaches. The model includes cannibalization, event-impact analysis, patent-expiry and erosion curves, and scenario and sensitivity analysis. All assumptions and sources are documented.

Primary & Secondary Research Framework

Secondary research draws on peer-reviewed literature, registries, regulatory and HTA sources, trial registries and company disclosures. Primary research includes in-depth interviews with physicians and payers on our panel, with Gorlin interviews conducted during 2025–2026.

Forecast Validation & Quality Controls

Bottom-up forecasts are validated against a top-down view. Epidemiology is cross-checked against published benchmarks and population denominators, and outputs are reconciled across the patient funnel before release. We incorporate the latest updates before each release.

Report Scope

Report Deliverables

Includes Report (PDF), Epidemiology model (Excel), Market forecast model (Excel), along with regular updates, customization, and consultant support.

Coverage

G8 Markets (US, EU5, Japan, and China) and Global/Top 30 Markets (US, Germany, France, Italy, Spain, UK, Japan, China, Canada, Australia, South Korea, India, Saudi Arabia, UAE, Netherlands, Switzerland, Sweden, Denmark, Norway, Finland, Belgium, Austria, Ireland, Poland, Turkey, Russia, Mexico, Brazil, Argentina, New Zealand, and Singapore).

Key Business Questions Answered

  1. How large is the current and forecast Gorlin syndrome market opportunity through 2036, by geography (G8) and drug class?
  2. Which emerging topical, systemic, and locally delivered therapies pose the greatest competitive threat to today's off-label standards of care, including surgery, hedgehog inhibitors (vismodegib, sonidegib), and topical agents?
  3. How will treatment share shift as the first Gorlin-specific preventive therapy, such as topical patidegib (SGT-610), moves ahead of reactive tumor removal in the treatment algorithm?
  4. Where does the greatest unmet need and white-space opportunity exist, by patient segment (tumor burden, PTCH1 vs. SUFU, age cohort), by manifestation (BCC prevention, odontogenic keratocysts, non-cutaneous features), or by geography?
  5. What pricing, access, and reimbursement dynamics will shape commercial uptake of a first-in-class rare-disease therapy across the G8 markets?
  6. How are the upcoming Phase 3 readouts, including the SGT-610 topline expected in late November 2026, likely to influence clinical guidelines, specialist adoption, and prescribing behavior?
  7. What is the diagnosed and drug-treated patient pool by country, and how is it expected to evolve through 2036 as genetic testing and early diagnosis improve?
  8. Which strategic partnerships, licensing deals, regulatory milestones, and pipeline assets (e.g., patidegib, SUBA-itraconazole) should stakeholders monitor for near-term market disruption?

Deliverables and file types

Included
Interactive Excel epidemiology model
Excel market forecast model with dashboard –
Full analyst report (PowerPoint) – –

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies – profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)

A look inside the report

Blurred previews. Click any figure to request it.
See the real pages first. Request a free sample of this report. Get the Free Sample

Before you buy

  • That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.

Tags:

  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma market
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma market research
  • Recurrent Head And Neck Cancer Squamous Cell Carcinoma market insight

Select file type

Choose the file type you want to purchase or request.

Markets

Select markets to include.

  • Secure checkout
  • 48 to 72 hours

Recently viewed reports

No recently viewed reports yet. Reports you open will appear here.
Need help or guidance?

Not sure which report fits your question? Our team will point you to the right one.

Custom research

Can't find the exact report you need?

Tell us what you are looking for and we will tailor the research to your indication, markets and questions.

Build your request

    I need for covering .

    Prefer to talk it through? Email clientsupport@thelansis.com

    Thanks, , we have your request

    You asked for for covering . We will reply to .


      We use your details only to send what you asked for. Read our privacy policy.

      Contact Us

      Fill in your details and our expert consultants will get in touch with you.

        * Required fields are marked

          Request Bundle Discount

          Get exclusive pricing for report bundles.

          *
          Required fields are marked












          Your information is secure and confidential.

            Request Epilansis Demo

            See how Epilansis can support your business.

            *
            Required fields are marked












            Your information is secure and confidential.

            Request your free sample

            Tell us where to send it. It takes under a minute.